Resource Library

Discover Kymera’s research and resources on our exciting platform, pipeline, and additional cutting-edge technologies.

  • Programs & Targets

  • Indications

  • Year

  • Resource Type/Format

  • Development Stage

Related Resources


July 12, 2021

Targeting STAT3 with Selective Protein Degraders for the Treatment of PTCL

13th Annual T-Cell Lymphoma Forum
PTCL
Read More
February 16, 2021

Discovery of Potent and Selective STAT3 Targeted Protein Degraders with Excellent in vitro and in vivo ADME Properties

Oxford Global’s Virtual Symposium: Targeted Protein Degradation & PROTAC
Liquid Tumors Solid Tumors
Read More
December 7, 2020

Mechanisms of Anti-Tumor Activity of STAT3 Degraders in Lymphoma

62nd American Society of Hematology (ASH) Virtual Annual Meeting and Exposition
Liquid Tumors
Read More
June 22, 2020

A STAT3-selective targeted protein degrader decreases the immune-suppressive tumor microenvironment and drives anti-tumor activity in preclinical models

American Association for Cancer Research (AACR) Virtual Annual Meeting II
Liquid Tumors Solid Tumors
Read More
December 7, 2019

Small molecule-induced, selective STAT3 degradation leads to anti-tumor activity in STAT3-dependent heme malignancies

American Society of Hematology (ASH) Annual Meeting
Liquid Tumors
Read More
October 26, 2019

Discovery of KYM-003, a potent and selective STAT3 degrader with anti-tumor activity in heme malignancies 

AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
Liquid Tumors
Read More